)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Inari Medical (NARI) investor relations material
Inari Medical Jefferies London Healthcare Conference 2024 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2024 summary20 Nov, 2024
Strategic overview and growth drivers
Inari Medical focuses on venous thromboembolism (VTE) with two purpose-built platforms for PE and DVT, treating over 165,000 patients since 2016.
Three main growth drivers: VTE market development, expansion into four adjacent markets, and international growth across 15+ countries.
U.S. VTE market represents a $6B TAM with only 8% penetration by Inari's platforms, indicating significant runway for growth.
International expansion is accelerating, with regulatory progress in Japan and China expected to drive further growth.
The Limflo acquisition targets a $1.5B TAM in CLTI, with commercial ramp and integration progressing as planned.
Market penetration and clinical evidence
Mechanical thrombectomy penetration in PE/DVT is around 10%, with expectations to approach STEMI's 90% over the next 5–10 years as evidence and guidelines evolve.
The Peerless I RCT demonstrated FlowTriever's superiority over catheter-directed thrombolysis, reducing hospital stay and 30-day readmission rates by 60%.
Peerless I results are expected to accelerate share shift from CDT to FlowTriever, representing a $150M revenue opportunity.
Ongoing RCTs (Peerless II, PERSEVERE, DEFYONCE) aim to further validate Inari's therapies against standard care and in high-risk populations.
Robust clinical data generation is seen as a key commercial and scientific inflection point, mirroring adoption curves in heart attack and stroke.
Financial performance and profitability
Achieved $13M sequential operating income improvement in Q3, with SG&A and R&D expenses stabilizing as a percent of sales.
On track for GAAP EBIT breakeven in Q4 and sustained operating profitability in the first half of 2025.
Continued disciplined investment in commercial infrastructure, clinical data, emerging therapies, and international expansion.
Operating leverage expected to increase as incremental investment needs slow and international/emerging therapies scale.
Overseas ASPs and gross margins remain strong, supporting a durable mid-80s percent gross margin profile.
Assess Limflo's integration and commercial progress.
What's driving Inari's path to profitability?
When might Peerless II & DEFYENCE data be available?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Inari Medical, Inc. develops, manufactures, markets, and sells its own line of devices for the interventional treatment of deep vein thrombosis, other arterial and venous diseases and cancerous lesions in the United States. The medical devices are inserted into the body either through an opening in the skin or a regionally accessed blood vessel or structure. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage